The different MOA of Ac-RLYE, which is based on the direct inhibition of the VEGF-VEFR-2 interaction rather than capturing soluble VEGF as the anti-VEGF antibody therapy, and the lower molecular weight and higher volume of distribution in ocular tissues can potentially contribute to the therapeutic efficacy of Ac-RLYE, which had a duration of 4–6 weeks at or above the dose of 20 μg/eye (intravitreal injection) in AMD animal models. The gene discussed is VEGFA; the disease is age-related macular degeneration.